Halberd Continues In-Vitro Successes With Elimination of Protein Linked to Depression

Author's Avatar
Apr 04, 2022

JACKSON CENTER, PA / ACCESSWIRE / April 4, 2022 / Halberd Corporation (OTC PINK:HALB) demonstrated the extracorporeal elimination of C-Reactive Protein from cerebral spinal fluid (CSF) by exposure to tuned laser light, in vitro. Halberd, encouraged by its recent success in eliminating all ten of the top antigens associated with PTSD (Post Traumatic Stress Disorder), CTE (Chronic Traumatic Encephalopathy) and numerous other neurodegenerative diseases, expanded their research to address elimination of the disease antigen associated with clinical depression - C-Reactive Protein[1]. According to the National Institute of Mental Health, "Major depression is one of the most common mental disorders in the United States."[2] An estimated 21 million Americans experienced at least one major depression episode in 2020. This represents about 8.4% of the population.